NASDAQ · PCVX
Vaxcyte, Inc.
$62.61+$1.15 (+1.87%)
Vaxcyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.01% below the high.
Loading market information…
NYSE · TFX · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Teleflex Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Teleflex Incorporated’s forward annual dividend is $1.36 per share, paid quarterly. The forward yield is 0.96% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Teleflex Incorporated’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $1.90. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Teleflex Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 1, 2025 | $2.91+1.04% vs estimate | $700.67M-8.54% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $3.89+0.78% vs estimate | $795.41M+3.68% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | $3.49+3.25% vs estimate | $764.38M-6.02% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
29 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $156.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$62.61+$1.15 (+1.87%)
Vaxcyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.01% below the high.
$324.55+$3.13 (+0.97%)
Krystal Biotech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.16% below the high.
$58.08+$0.68 (+1.18%)
TG Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
$60.49+$0.28 (+0.47%)
Arrowhead Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.65% below the high.
$45.37+$0.12 (+0.27%)
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
$20.40$0.00 (0.0%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.49% below the high.
$93.39+$1.18 (+1.28%)
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
$20.24+$0.81 (+4.17%)
Stevanato Group S.p.A.’s quoted price sits in the upper half of its reported 52-week range, 25.04% below the high.
